Environmental factors and drug titration in heart failure
Section: Artículos Científicos
How to quote
Enferm Cardiol. 2019;26(76):69-73
Authors
Concepción Cruzado Álvarez1, Yolanda Sánchez Paule2.
Position
1 Doctora en Ciencias de la Salud por la Universidad de Málaga. Enfermera Unidad Insuficiencia Cardiaca del Hospital Virgen de la Victoria de Málaga. 2 Licenciada en Antropología. Enfermera Unidad Insuficiencia Cardiaca del Hospital Virgen de la Victoria de Málaga.
Contact address
Concepción Cruzado Álvarez. C/Antígona, 1, 2N. 29010 Málaga
Contact email: ccruzadoalvarez@gmail.com
Abstract
Introduction and objectives. The emergence of new drugs for Heart Failure (HF) and the development of treatment strategies have made it possible to substantially improve the prognosis of this disease. 2016 guidelines include treatment with sacubitril/valsartan (SAC / VAL), a neprilysin and angiotensin receptor inhibitor (ARNi). For the heart failure specialist nurse, in addition to the risk of angioedema if administered together with the ACEi, the risk of hypotension due to the drug stands out. The aim of this work is to assess whether climatic conditions influence the SAC / VAL titrations in patients with HF.
Material and methods. All patients referred to the nursing consultation for SAC/VAL titration between 4th October 2016 and 31st July 2017 were retrospectively studied. Demographic and clinical variables from the patients and variables relating to the pharmacological treatment were studied. They were assigned into two groups, patients titrated until 30th April and those titrated thereafter.
Results. 103 patients were studied. Regarding SAC/VAL, 39.6% reached the dose of 24/26 mg, 29.1% that of 49/51 mg and 34% the dose of 97/103 mg. Significant differences are observed in the SAC/VAL dose in both groups, p<0.001. In addition, 20.3% of those patients titrated before 30th April presented hypotension related to the change of season.
Conclusions. The obtained results suggest that climatic conditions influence drug titration in HF patients.
Keywords:
cardiovascular nursing; heart failure; pharmacology; climate; blood pressure
Versión en Español
Título:
Factores medioambientales y titulación de fármacos en insuficiencia cardiaca
Artículo completo no disponible en este idioma / Full article is not available in this language
Bibliography
1. Anguita M, Manito N. Sacubitrilo/valsartán: una nueva referencia en el tratamiento de la insuficiencia cardiaca con fracción de eyección reducida. Madrid: Sociedad Española de Cardiología; 2017.33p.
2. Bayes-Genis A, Lupón J. Neprilisina: indicaciones, expectativas y retos. Rev Esp Cardiol. 2016;69(7):647-9.
3. Owens AT, Brozena SC, Jessup M. New management strategies in heart failure. Circ Res. 2016;118(3):480-95.
4. Oyangurena J, Latorre PM, Torcal J, Lekuona I, Rubio S, Maull E, Grandes G. Efectividad y determinantes del éxito de los programas de atención a pacientes con insuficiencia cardiaca: revisión sistemática y metanálisis. Rev Esp Cardiol. 2016;69:900-14.
5. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, Havranek EP, Lee CS, Lindenfeld J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009 Sep22;120(12):1141-63.
6. González B, Lupón J, Parajón T, Urrutia A, Herreros J, Valle V. Aplicación de la escala europea de autocuidado en insuficiencia cardíaca (EHFScBS) en una unidad de insuficiencia cardíaca en España. Rev Esp Cardiol. 2006;59(2):166-70.
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
8. Fares A. Winter Hypertension: Potential mechanisms. Int J Health Sci (Qassim). 2013 Jun;7(2):210-219.
9. Torres-Pérez LF, Morales-Asencio JM, Jiménez-Garrido M, Copé-Luengo G, Sánchez-Gavira S, Gómez-Rodríguez JM. Impacto del autocuidado y manejo terapéutico en la utilización de los recursos sanitarios urgentes por pacientes crónicos: estudio de cohortes. Emergencias. 2013;25:353-360.
10. Jhund PS, Fu M, Bayram E, Chen C‑H, Negrusz‑Kawecka M, Rosenthal A, et al. Efficacy and safety of LCZ696 (sacubitril‑valsartan) according to age: insights from PARADIGM‑HF. Eur Heart J. 2015;36:2576‑84.
11. Kazuomi K, NaokoT, Hiroshi K, NobuhikoY, Masafumi N, Takeshi F. Development of a New ICT-Based Multisensor Blood Pressure Monitoring System for Use in Hemodynamic Biomarker-Initiated Anticipation Medicine for Cardiovascular Disease: The National IMPACT Program Project. Progress in Cardiovascular Diseases. 2017;60:435-449.
12. Annick MD, Jean-Marc MS, Olivier MD. Relationship Between Blood Pressure and Outdoor Temperature in a Large Sample of Elderly Individuals. Arch Intern Med. 2009;169(1):75-80.
13. Bhatnagar A. Environmental Determinants of Cardiovascular Disease. Circ Res. 2017;121(2):162-180.
14. Brennan PJ, Greenberg G, Miall WEThompson SG. Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) 1982; 285 (6346) 919- 923.
